What is OPKO Health
OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company develops treatments for secondary hyperparathyroidism, and has recently finished the patient recruitment for a Phase III trial against insufficiency in Vitamin D.
Company Overview
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency and VARUBI for chemotherapy-induced nausea and vomiting. We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.
Investor Relations
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 420-person salesforce to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Former shareholders of Bio-Reference Laboratories, Inc. that have questions related to the exchange of BRLI shares to OPK shares, please contact our exchange agent, American Stock Transfer & Trust Company.
Opko Health reports of human growth hormone product
. Opko Health Inc. OPK, 18.85% said Friday a late-stage trial of a human growth hormone product failed to meet its main goal, but said multiple outliers may have affected the result and pledged to further review the patients. Opko said it has now started a Phase 3 study of the product in children to measure its efficacy versus daily injections of Genotropin, a prescription therapy for children and adults with growth issues.
Top Placebo in Trial
The company said it identified one or more outliers that may have impacted the primary outcome of the phase-3 trial and said it is undertaking further review of the study population to try to see if any outliers can be excluded from the final analysis. OPKO Health Inc. on Friday said its weekly injection to treat growth hormone deficiency failed to achieve its primary goal compared with a placebo in a late-stage trial.
